A new tool for monitoring immune health patterns over time has revealed how a pair of checkpoint inhibitor therapies works together to recruit new cancer-fighting T cells with every infusion.

The study challenges fundamental assumptions about how a common immunotherapy drug combination activates different types of T cells to defeat cancer and could help researchers more precisely measure immune response in future clinical trials.

Immune checkpoint inhibitors work by unleashing T cells to find and kill cancer cells.